Physician profile
Robert E Maslo
NPI 1972892677
$2,699.27
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $803 · 2021: $279 · 2022: $11.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $324.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $241.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.47 | 2019-2021 | |
| Lilly USA, LLC | $187.58 | 2019-2021 | |
| Amarin Pharma, INC. | $146.46 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $131.03 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $107.96 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.64 | 2019-2020 | |
| Pfizer INC. | $99.64 | 2019 | |
| Amgen INC. | $97.45 | 2019-2020 | |
| Abbvie INC. | $93.46 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $84.36 | 2019 | |
| Horizon Therapeutics Plc | $66.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $60.77 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $46.54 | 2019 | |
| Astellas Pharma US INC | $39.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $39.02 | 2019 | |
| Sanofi Pasteur INC. | $36.36 | 2019 | |
| Glaxosmithkline, LLC. | $31.36 | 2020 | |
| Allergan, INC. | $29.63 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.53 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.90 | 2019 | |
| Genentech USA, INC. | $13.88 | 2019 | |
| Adlon Therapeutics L.P. | $13.62 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.71 | 2019 | |
| Ibsa Pharma INC. | $12.37 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.92 | 2019 | |
| Abbott Laboratories | $11.85 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maslo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.